Lehrman Biopharma consulting has accomplished the
following:
following:
Past successes / Current partners
 |
| |
 |
| |
 |
| |
 |
 | Enhanced bioavailability and increased in vivo half-life by | |
| modifying protein structure and small molecule salt form. Each of these candidates proceeded to clinical trials. | ||
| Identified challenges and managed risks to candidate | |
| development. | ||
| Screened and selected dosage forms. At least one marketed | |
| product utilizes the selected formulation. Other formulations are in clinical trials. | ||
| Help establish a rationally-based taste-masked formulation | |
| that is now in clinical trials. | ||
| Developed robust analytical methods for final product | |
| characterization and stability testing. In some cases, these methods have been transferred to contract laboratories. | ||
| Selected and managed contract organizations that | |
| manufactured cGMP compliant drug substance and drug product. | ||
| Authored documents in support of regulatory filings. |
Current clients:
- Serving as an expert witness to a mid-size pharmaceutical
company in support of patent litigation. - Writing case studies to help train high level management new
to the specific challenges of pharmaceutical development.- Establishing chemical development plans for a new company
interested in improved therapeutics for strengthening bone.
Of special interest:
Protein aggregation is a critical concern to companies that
are developing biotechnology-derived drugs. Russ has
significant experience and expertize in this area. Check his
recent article on this topic:
- Writing case studies to help train high level management new